PDCD1 and neoplasm: Bispecific antibodies (bsAbs) that bind PD-1/PD-L1 together with a second checkpoint or a costimulatory receptor are designed to co-localize checkpoint blockade and conditional engagement of immune cells within the tumor microenvironment, potentially increasing therapeutic efficiency while limiting off-tumor activity.